KHB(SZ:002022)2025-02-05 08:15Financial Performance - The company expects a net loss of between 530 million yuan and 650 million yuan for the fiscal year 2024, compared to a net loss of 234.01 million yuan in the same period last year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be a loss of between 558 million yuan and 678 million yuan, compared to a loss of 280.01 million yuan in the previous year[3]. - Basic earnings per share are expected to be a loss of between 1.0496 yuan and 1.2873 yuan, compared to a loss of 0.4550 yuan per share last year[3]. Performance Challenges - The decline in performance is primarily due to intensified industry competition and price reductions, leading to decreased sales revenue despite an increase in sales volume for some reagent products[5]. - Decreased financial income and government subsidies compared to the previous year have contributed to reduced profit contributions[6]. Investment and Strategy - The company has maintained high R&D investment in immunodiagnostics, molecular diagnostics, and biochemical diagnostics, which has impacted profits[5]. - Marketing expenses remain high as the company adjusts its sales strategy and expands its domestic and international market presence[6]. - The company plans to continue focusing on high-quality sustainable development and innovation to find new growth curves[6]. - The company will enhance its international competitiveness by improving sales and service channels and accelerating overseas market expansion[6]. Information Disclosure - Specific financial data will be disclosed in the annual report for 2024, with the company committed to timely information disclosure[7].